ライフサイエンスコーパス: gonorrhoeae

1 infected with antibiotic-resistant Neisseria gonorrhoeae).

2 namics of RMS and methylation patterns in N. gonorrhoeae.

3 t the radiant exposure used to inactivate N. gonorrhoeae.

4 that is conserved and surfaced exposed in N. gonorrhoeae.

5 gH1 to target the same enzyme from Neisseria gonorrhoeae.

6 ting studies against organisms other than N. gonorrhoeae.

7 xygen was involved in aBL inactivation of N. gonorrhoeae.

8 ynamics of microcolonies formed by Neisseria gonorrhoeae.

9 the generation of antibodies recognizing N. gonorrhoeae.

10 logical approach, for the inactivation of N. gonorrhoeae.

11 is of the closely related species, Neisseria gonorrhoeae.

12 meningitidis, no vaccine is available for N. gonorrhoeae.

13 bited rapid bactericidal activity against N. gonorrhoeae.

14 s in PBP2 underpins the ESC resistance of N. gonorrhoeae.

15 able expression amongst strains of Neisseria gonorrhoeae.

16 /mL for C. trachomatis and 1500CFU/mL for N. gonorrhoeae.

17 the global threat of multidrug-resistant N. gonorrhoeae.

18 exposure and decreased susceptibility of N. gonorrhoeae.

19 exposure and decreased susceptibility of N. gonorrhoeae.

20 mmon sexually transmitted pathogen Neisseria gonorrhoeae.

21 ections: Chlamydia trachomatis and Neisseria gonorrhoeae.

22 o modulate biofilm accumulation by Neisseria gonorrhoeae.

23 bal spread of antibiotic-resistant Neisseria gonorrhoeae.

24 uishable from infections caused by Neisseria gonorrhoeae.

25 ce for bacterial pathogens such as Neisseria gonorrhoeae.

26 IL-8 by endocervical cells infected with N. gonorrhoeae.

27 rce of antimicrobial resistance in Neisseria gonorrhoeae.

28 DA-approved gold-containing drugs against N. gonorrhoeae.

29 against an important eye pathogen, Neisseria gonorrhoeae.

30 both Streptococcus pneumoniae and Neisseria gonorrhoeae.

31 %; P = 0.005), C. trachomatis (6.2%), and N. gonorrhoeae (1.4%).

32 sting was 8.5% for C trachomatis, 7.1% for N gonorrhoeae, 16.1% for T vaginalis, 18.1% for bacterial

33 ed for C. trachomatis (887 specimens) and N. gonorrhoeae (890 specimens) at the Children's Hospital o

34 and diagnostic escape variants in Neisseria gonorrhoeae, a pathogen associated with a high burden of

35 Neisseria gonorrhoeae (adjusted odds ratio [AOR], 1.75; P = .103),

36 spatus, Gardnerella vaginalis, and Neisseria gonorrhoeae All vaginal microbiota and N. gonorrhoeae ef

37 stasis affecting antibiotic resistance in N. gonorrhoeae and a generalizable approach for epistatic g

38 technology to examine the epidemiology of N. gonorrhoeae and associated AMR in the Australian populat

39 gative percent agreement for detection of N. gonorrhoeae and C. trachomatis for 3 investigational ass

40 gative percent agreement for detection of N. gonorrhoeae and C. trachomatis for three investigational

41 e detection of both pharyngeal and rectal N. gonorrhoeae and C. trachomatis.

42 e detection of both pharyngeal and rectal N. gonorrhoeae and C.trachomatis.

43 lection of urethral discharge to diagnose N. gonorrhoeae and Chlamydia trachomatis infection in certa

44 Pharyngeal and rectal Neisseria gonorrhoeae and Chlamydia trachomatis play important rol

45 sserial heparin-binding antigen (NHBA) of N. gonorrhoeae and confirm its role in binding to several g

46 -based tool for genomic contact tracing of N gonorrhoeae and demonstrate local, national, and interna

47 pects of the colonization and survival of N. gonorrhoeae and may be a target for new antimicrobial or

48 Neisseria gonorrhoeae and Neisseria meningitidis are closely-relat

49 However, only infection with pathogenic N. gonorrhoeae and not infection with the other bacteria te

50 he monoglyceride monocaprin rapidly kills N. gonorrhoeae and other bacterial species and is non-irrit

51 Quinolone-resistant N. gonorrhoeae and reduced cefixime susceptibility appear a

52 n males was significantly higher than the N. gonorrhoeae and T. vaginalis infection rates.

53 (ii) swabs seeded with C. trachomatis and N. gonorrhoeae and then placed in transport medium were tes

54 me (OR, 0.24; 95% 0.09, 0.66), and Neisseria gonorrhoeae and/or Chlamydia trachomatis had 92% lower o

55 ples spiked with either C. trachomatis or N. gonorrhoeae, and also containing both bacteria.

56 such as Salmonella spp, Campylobacter spp, N gonorrhoeae, and H pylori.

57 eographical and temporal spread of AMR in N. gonorrhoeae, and improved understanding of the pharmacok

58 tube epithelial cells were infected with N. gonorrhoeae, and MMP patterns were examined.

59 on incident Chlamydia trachomatis, Neisseria gonorrhoeae, and Mycoplasma genitalium infection.

60 olone-resistant Campylobacter spp, Neisseria gonorrhoeae, and Salmonella typhi were included in the h

61 entified similar numbers of C trachomatis, N gonorrhoeae, and T vaginalis infections, but much higher

62 y rates for Chlamydia trachomatis, Neisseria gonorrhoeae, and Trichomonas vaginalis DNA, detected usi

63 ecimens for Chlamydia trachomatis, Neisseria gonorrhoeae, and Trichomonas vaginalis via commercial tr

64 ee well-defined species (N. meningitidis; N. gonorrhoeae; and Neisseria polysaccharea) and genomes of

65 ting several resistance threats including N. gonorrhoeae AR-Ng testing, a subactivity of the CDC's AR

66 e rising, and antibiotic-resistant Neisseria gonorrhoeae (AR-Ng) is an urgent public health threat.

67 ncy, and Chlamydia trachomatis and Neisseria gonorrhoeae are recognized microbial causes.

68 Chlamydia trachomatis and Neisseria gonorrhoeae are the two most common causes of sexually t

69 ork supported the laboratory capacity for N. gonorrhoeae AST and associated genetic marker detection,

70 e primary outcome was clearance of Neisseria gonorrhoeae at all initially infected sites, defined as

71 rug and had a positive genital culture for N gonorrhoeae at baseline.

72 ipants were tested for C. trachomatis and N. gonorrhoeae at three sites (anorectum, pharynx, and uret

73 Neisseria gonorrhoeae bacteria are acknowledged as an urgent threa

74 on of patients with eradication of genital N gonorrhoeae based on culture at test of cure, assessed i

75 The primary mechanism by which N. gonorrhoeae becomes resistant to ESCs is by acquiring a

76 Ac(2) and Neu5Ac9N(3) into LOS results in N. gonorrhoeae being fully serum sensitive.

77 her, the study identifies transmission of N. gonorrhoeae between HIV-positive and HIV-negative indivi

78 uenzner and Hauck (2020) find that Neisseria gonorrhoeae blocks exfoliation by producing nitric oxide

79 o detect Chlamydia trachomatis and Neisseria gonorrhoeae, but no commercial tests are cleared by the

80 sed to investigate transmission of Neisseria gonorrhoeae, but to date, most studies have not combined

81 nofin reduced the burden of intracellular N. gonorrhoeae by over 99% outperforming the drug of choice

82 cal urine and swab specimens positive for N. gonorrhoeae by the Cobas assay, 71% could be genotyped.

83 Infrequently, Neisseria gonorrhoeae can cause disseminated gonococcal infection

84 The obligate human pathogen Neisseria gonorrhoeae carries one of the highest loads of RMS in i

85 Chlamydia trachomatis and Neisseria gonorrhoeae cases reached a record high in the United St

86 s two, Neisseria meningitidis, and Neisseria gonorrhoeae, cause invasive disease: the other eight are

87 N. gonorrhoeae causes the sexually transmitted disease gono

88 The bacterium Neisseria gonorrhoeae causes the sexually transmitted infection (S

89 A antibodies that bound to the surface of N. gonorrhoeae cells, as shown by indirect fluorescent anal

90 genome multilocus sequence typing scheme (N gonorrhoeae cgMLST v1.0).

91 NGU was considered idiopathic when Neisseria gonorrhoeae, Chlamydia trachomatis, Mycoplasma genitaliu

92 inistration of CMP-Leg5,7Ac(2) attenuated N. gonorrhoeae colonization of mouse vaginas.

93 administered intravaginally (10 mug/d) to N. gonorrhoeae-colonized mice were equally efficacious.

94 The objective of this work was to assess N. gonorrhoeae confirmation in over 13,000 N. gonorrhoeae s

95 N. gonorrhoeae could also be detected from urine in cobas P

96 Neisseria gonorrhoeae culture is necessary to determine antimicrob

97 post collection, 100% yielded concordant N. gonorrhoeae culture results compared to immediate proces

98 tivity of patient-collected specimens for N. gonorrhoeae culture.

99 ed specimens are comparably sensitive for N. gonorrhoeae culture.

100 We performed N. gonorrhoeae cultures on paired, clinician- and patient-c

101 Neisseria gonorrhoeae cultures were obtained at baseline and test

102 med a meta-analysis of seven large Neisseria gonorrhoeae datasets, as well as Klebsiella pneumoniae a

103 Neisseria gonorrhoeae deploys a unique immune evasion strategy whe

104 Here, we show an N. gonorrhoeae diagnostic workflow for analysis of metageno

105 ction methods that maximize the amount of N. gonorrhoeae DNA sequenced while minimizing contaminating

106 e sequencing can detect sufficient Neisseria gonorrhoeae DNA to reconstruct whole genomes directly fr

107 ia gonorrhoeae All vaginal microbiota and N. gonorrhoeae efficiently colonized the 3-D surface, local

108 The human-restricted pathogen Neisseria gonorrhoeae encodes a single N-acetylmuramyl-l-alanine a

109 he ceftriaxone plus azithromycin group had N gonorrhoeae eradication at test of cure (difference -4.0

110 mice to study mechanisms by which Neisseria gonorrhoeae evades host-derived antimicrobial factors an

111 We demonstrate for the first time that N. gonorrhoeae exploits this host strategy in a novel defen

112 These data demonstrate that N. gonorrhoeae filamentous phage can induce antibodies with

113 rolide use and azithromycin resistance in N. gonorrhoeae, finding that population-wide macrolide use

114 7 proteins important for DNA secretion by N. gonorrhoeae for protein interactions.

115 81% sensitivity and 100% specificity for N. gonorrhoeae from isolates with a representative database

116 The sensitivity of Xpert for N. gonorrhoeae from rectal swabs was 100% (95% CI, 88 to 10

117 ntamicin alone failed to eradicate Neisseria gonorrhoeae from the pharynx.

118 Gentamicin alone failed to eradicate N. gonorrhoeae from the pharynx.

119 ave receptive anal intercourse for Neisseria gonorrhoeae (GC) and Chlamydia trachomatis (CT).

120 However, disentangling the N. gonorrhoeae genome from metagenomic samples and robustly

121 thral gonorrhea can recover near-complete N. gonorrhoeae genomes.

122 amydia trachomatis (chlamydia) and Neisseria gonorrhoeae (gonorrhea) infections in women.

123 nfluenzae, Neisseria meningitidis, Neisseria gonorrhoeae, Helicobacter pylori, Moraxella catarrhalis,

124 trachomatis and rectum and oropharynx for N. gonorrhoeae Hence, extragenital screening is critical fo

125 n of nucleic acid amplification tests for N. gonorrhoeae identification, the capacity for culturing N

126 cy and showed its efficacy against Neisseria gonorrhoeae in a mouse vaginal infection model.

127 the level of antimicrobial resistance in N. gonorrhoeae in different settings.

128 sensitivity of Cobas for the detection of N. gonorrhoeae in female specimens was 94.8% (95% CI, 89.6%

129 ty and specificity of Cobas for detecting N. gonorrhoeae in male urine were 100.0% (95% CI, 95.8% to

130 and cefixime-resistant strains of Neisseria gonorrhoeae in MSM in England, which was applied to data

131 o studies of growth and in the survival of N gonorrhoeae in primary cervical epithelial cells.

132 ssay (Xpert) to detect C. trachomatis and N. gonorrhoeae in rectal and pharyngeal samples from 224 me

133 rehensive detection of C. trachomatis and N. gonorrhoeae in the pediatric population.

134 dentification, the capacity for culturing N. gonorrhoeae in the United States has declined, along wit

135 The requirement to confirm N. gonorrhoeae in validated samples is not required for all

136 tion and alters the infection dynamics of N. gonorrhoeae in vitro Furthermore, miR-718 regulates the

137 glucose inhibited 48 clinical isolates of N. gonorrhoeae including multidrug-resistant strains at a c

138 cated that aBL preferentially inactivated N. gonorrhoeae, including antibiotic-resistant strains, ove

139 ng of FH/FHL-1 through domains 6 and 7 to N. gonorrhoeae increased with truncation of the heptose I (

140 We previously reported FH binding to N. gonorrhoeae independently of lipooligosaccharide (LOS) s

141 he beta-strands at the gate interface for N. gonorrhoeae, indicating that the gate is dynamic.

142 n populations at high risk of contracting N. gonorrhoeae induces an increase in MIC and may result in

143 n populations at high risk of contracting N. gonorrhoeae induces an increase in MIC, and may result i

144 This series describes cases of N. gonorrhoeae infection among patients receiving eculizuma

145 iated with bacterial burden during Neisseria gonorrhoeae infection and alters the infection dynamics

146 are Gram stain testing to diagnose Neisseria gonorrhoeae infection and nongonococcal urethritis (NGU)

147 nsequences of sexually transmitted Neisseria gonorrhoeae infection and probably involve an imbalance

148 Pre- and postmarketing safety reports of N. gonorrhoeae infection in patients receiving eculizumab w

149 Treatment of Neisseria gonorrhoeae infection is empirical and based on populati

150 atomic distribution of C. trachomatis and N. gonorrhoeae infection is needed to optimize future scree

151 considered for point-of-care diagnosis of N. gonorrhoeae infection or NGU in men, meatal swabs should

152 The burden of C. trachomatis and N. gonorrhoeae infection was significantly higher in the 14

153 Nine cases of N. gonorrhoeae infection were identified; 8 were classified

154 is infection, 0.56 [95% CI, .19-1.67] for N. gonorrhoeae infection, and 0.66 [95% CI, .38-1.15] for M

155 lizumab dose within the 3 months prior to N. gonorrhoeae infection.

156 rovide reliable diagnostic information in N. gonorrhoeae infection.

157 The majority of oropharyngeal Neisseria gonorrhoeae infections are asymptomatic, and many infect

158 Most oropharyngeal Neisseria gonorrhoeae infections are asymptomatic, and many infect

159 iological investigation demonstrated that N. gonorrhoeae infections are dominated by relatively few s

160 ssed the positivity of C. trachomatis and N. gonorrhoeae infections at different anatomic sites in a

161 influence detection of C. trachomatis and N. gonorrhoeae infections at specific anatomic testing site

162 data on the burden of C. trachomatis and N. gonorrhoeae infections by anatomic site is lacking in ch

163 versal testing detected more oropharyngeal N.gonorrhoeae infections compared to selective testing, of

164 fication tests (NAATs) to diagnose Neisseria gonorrhoeae infections complicates the performance of a

165 g identified 92-100% of C. trachomatis or N. gonorrhoeae infections in participants assigned female a

166 , the sensitivity of PS testing to detect N. gonorrhoeae infections increased to 94%.

167 that the prevalence of C. trachomatis and N. gonorrhoeae infections is much higher in extragenital so

168 ersal testing detected more oropharyngeal N. gonorrhoeae infections than selective testing, of which

169 ly more prevalent than C. trachomatis and N. gonorrhoeae infections, while the M. genitalium infectio

170 lth efforts to control C. trachomatis and N. gonorrhoeae infections.

171 . trachomatis) and Neisseria gonorrhoeae (N. gonorrhoeae) infections.

172 Multidrug-resistant Neisseria gonorrhoeae is a global health problem.

173 Antimicrobial resistance in Neisseria gonorrhoeae is a major issue of public health, and there

174 nding the evolutionary dynamics of Neisseria gonorrhoeae is a significant public and global health pr

175 he rise of antimicrobial-resistant Neisseria gonorrhoeae is a significant public health concern.

176 Multidrug-resistant Neisseria gonorrhoeae is a top threat to public health.

177 Neisseria gonorrhoeae is an urgent public health threat due to rap

178 or public health concern globally is that N. gonorrhoeae is evolving high levels of antimicrobial res

179 ead of antimicrobial resistance in Neisseria gonorrhoeae is globally recognised.

180 The sexually transmitted pathogen Neisseria gonorrhoeae is regarded as being on the way to becoming

181 f colonization and pathogenesis of Neisseria gonorrhoeae is required to aid development of new treatm

182 Gonorrhea, caused by the bacterium Neisseria gonorrhoeae, is a globally prevalent sexually transmitte

183 All available N. gonorrhoeae isolates (n = 2452) received from Australian

184 losporin resistance-comprised 8.9% of all N. gonorrhoeae isolates and were primarily observed in male

185 In the United States, 19.2% of Neisseria gonorrhoeae isolates are resistant to ciprofloxacin.

186 n 1102 resistant and susceptible clinical N. gonorrhoeae isolates collected from 2000 to 2013 via the

187 Eight N. gonorrhoeae isolates collected from 7 patients on Oahu,

188 gonorrhoeae isolates from Australia, we show widespread

189 We included N. gonorrhoeae isolates of patients visiting the Amsterdam

190 We included N. gonorrhoeae isolates of patients who visited the Amsterd

191 ithromycin nonsusceptibility among Neisseria gonorrhoeae isolates threatens current treatment recomme

192 We identified a cluster of Neisseria gonorrhoeae isolates with high-level azithromycin resist

193 2018, the network tested 8,214 and 8,628 N. gonorrhoeae isolates, respectively, and the CDC received

194 study transmission and track resistance in N gonorrhoeae isolates.

195 Neisseria gonorrhoeae may have contributed to complications prior

196 dentify multilocus sequence types (MLST), N. gonorrhoeae multiantigen sequence types (NG-MAST), and m

197 currence of Chlamydia trachomatis, Neisseria gonorrhoeae, Mycoplasma genitalium, and Trichomonas vagi

198 a trachomatis (C. trachomatis) and Neisseria gonorrhoeae (N. gonorrhoeae) infections.

199 samples represent robust biospecimens for N. gonorrhoeae NAAT testing and may not require confirmatio

200 However, the specificity of N. gonorrhoeae NAATs may be suboptimal, particularly for ex

201 mmend the systematic screening for Neisseria gonorrhoeae (NG) and Chlamydia trachomatis (CT) infectio

202 y identify those with extragenital Neisseria gonorrhoeae (NG) and Chlamydia trachomatis (CT) so unive

203 enital testing misses extragenital Neisseria gonorrhoeae (NG) and Chlamydia trachomatis (CT).

204 Neisseria gonorrhoeae (NG) infections are a global health burden.

205 c susceptibility testing (AST) for Neisseria gonorrhoeae (Ng) is critically needed to counter widespr

206 k-based mathematical model of HIV, Neisseria gonorrhoeae (NG), and Chlamydia trachomatis (CT) transmi

207 of infection for the STD pathogen Neisseria gonorrhoeae (Ngo).

208 s As with N. meningitidis NspA (Nm-NspA), N. gonorrhoeae NspA (Ng-NspA) bound FH/FHL-1 through FH dom

209 Several Neisseria gonorrhoeae nucleic acid amplification tests (NAATs) wit

210 tion, we assessed the cross-reactivity to N. gonorrhoeae of serum raised to the meningococcal vaccine

211 In Neisseria gonorrhoeae, one of the first bacteria for which pan-res

212 boratory isolation or detection of Neisseria gonorrhoeae only from a clinical specimen, and controls

213 5% CI, 2.1-2.7), and concurrent anorectal N. gonorrhoeae (OR, 11.4; 95% CI, 10.6-12.3).

214 ; 95% CI, 1.9-2.1), concurrent urogenital N. gonorrhoeae (OR, 2.4; 95% CI, 2.1-2.7), and concurrent a

215 ual contact with either C. trachomatis or N. gonorrhoeae, or had symptoms of an STI.

216 nce of any bacterial STI (C. trachomatis, N. gonorrhoeae, or M. genitalium infection) was lower in th

217 .4,95%CI2.1-2.7), and concurrent anorectal N.gonorrhoeae (OR11.4,95%CI10.6-12.3).

218 OR2.0,95%CI1.9-2.1), concurrent urogenital N.gonorrhoeae (OR2.4,95%CI2.1-2.7), and concurrent anorect

219 icantly for C. trachomatis (P = 0.774) or N. gonorrhoeae (P = 0.163).

220 prevalent among HIV-infected MSM (Neisseria gonorrhoeae, P = .03; Mycoplasma genitalium, P = .04; HS

221 transfer between bacteria, and in Neisseria gonorrhoeae plasmids can mediate high-level antimicrobia

222 We observed N. gonorrhoeae positivity of 8.1% in the pharynx and 7.9% i

223 We observed N. gonorrhoeae positivity of 8.1% in the pharynx and 7.9% i

224 The T4SS from Neisseria gonorrhoeae possesses the unique ability to mediate DNA

225 c Chlamydia trachomatis Q(x) (CTQ)/Neisseria gonorrhoeae Q(x) (GCQ), Hologic Aptima Combo 2 (AC2) and

226 range for zoliflodacin against the Neisseria gonorrhoeae QC strain ATCC 49226 was defined as 0.06 to

227 rethral gonorrhea, >=92.8% coverage of an N. gonorrhoeae reference genome was achieved in all samples

228 Neisseria gonorrhoeae releases peptidoglycan fragments during grow

229 Neisseria gonorrhoeae represents an urgent public health threat du

230 Increasing Neisseria gonorrhoeae resistance to ceftriaxone, the last antibiot

231 8 and 154 patients for C. trachomatis and N. gonorrhoeae, respectively.

232 Deletion of amiC from N. gonorrhoeae results in severely impaired cell separation

233 . gonorrhoeae confirmation in over 13,000 N. gonorrhoeae screen-positive samples representing various

234 During infection, Neisseria gonorrhoeae senses and responds to stress; such response

235 atis sensitivity 58.3%, specificity 44.7%; N gonorrhoeae sensitivity 66.0%, specificity 45.2%; T vagi

236 tis (sensitivity 71.7%, specificity 100%), N gonorrhoeae (sensitivity 76.0%, specificity 100%), and T

237 The N. gonorrhoeae Sequence Typing for Antimicrobial Resistance

238 ous studies have demonstrated that Neisseria gonorrhoeae sialylates the terminal N-acetyllactosamine

239 We used N. gonorrhoeae-spiked urine samples and samples from gonorr

240 mydia trachomatis AC2 also detects Neisseria gonorrhoeae Storage and temperature conditions may impac

241 pecies, Neisseria meningitidis and Neisseria gonorrhoeae, straddle the border between commensalism an

242 derived from the decreased-susceptibility N. gonorrhoeae strain 35/02 and ESC-resistant strain H041.

243 The prevalence of mosaic PBP2 harboring N. gonorrhoeae strains highlight the ability for new N. gon

244 in being the most abundant species in all N. gonorrhoeae strains studied.

245 eae strains highlight the ability for new N. gonorrhoeae strains to spread and become established acr

246 All Neisseria gonorrhoeae strains whose DNA sequences have been determ

247 ected to rise due to the spread of Neisseria gonorrhoeae strains with decreased susceptibility to ext

248 ne showed an additive effect against four N. gonorrhoeae strains, suggesting the possibility of using

249 dissemination of antimicrobial-resistant N. gonorrhoeae strains.

250 ma genitalium, Mycoplasma hominis, Neisseria gonorrhoeae, Streptococcus agalactiae, Chlamydia trachom

251 Neisseria gonorrhoeae successfully overcomes host strategies to li

252 genotypic assay for prediction of Neisseria gonorrhoeae susceptibility to ciprofloxacin.

253 cid amplification tests for C trachomatis, N gonorrhoeae, T vaginalis, bacterial vaginosis, and vulvo

254 ssociated with the unique function of the N. gonorrhoeae T4SS as well as generic features of F-type T

255 The N. gonorrhoeae T4SS can be grouped with F-type conjugative

256 p data, irrespective of the baseline visit N gonorrhoeae test result.

257 aBL also effectively inactivated N. gonorrhoeae that had attached to and invaded into the va

258 t antibiotics in 1,102 isolates of Neisseria gonorrhoeae that were confirmed in a second dataset of 4

259 ltidrug-resistant bacteria such as Neisseria gonorrhoeae The first structure of BamA, the central com

260 lement-inhibitory activity, also binds to N. gonorrhoeae The ligand for both FH and FHL-1 was identif

261 e clinical features of C. trachomatis and N. gonorrhoeae, the 2 organisms that drive research agendas

262 Neisseria gonorrhoeae, the causative agent of gonorrhea, has evolv

263 Neisseria gonorrhoeae, the causative agent of gonorrhea, is an exc

264 Neisseria gonorrhoeae, the causative agent of the sexually transmi

265 he syndrome caused by its sister species, N. gonorrhoeae, the etiologic agent of gonorrhea.

266 thromycin complicates treatment of Neisseria gonorrhoeae, the etiologic agent of gonorrhea.

267 A, the central component of BAM, was from N. gonorrhoeae, the etiological agent of the sexually trans

268 those of Chlamydia trachomatis and Neisseria gonorrhoeae, the mechanisms by which this pathogen elici

269 For N. gonorrhoeae, the sensitivity of PS testing (90%) was sig

270 Neisseria gonorrhoeae, the sole causative agent of gonorrhea, cons

271 ithromycin usage and resistance in Neisseria gonorrhoeae threatens current dual treatment.

272 pulations in the susceptibility of Neisseria gonorrhoeae to antimicrobials, and the reasons for this

273 or misS severely reduced the capacity of N. gonorrhoeae to colonize mice or maintain infection over

274 Resistance of Neisseria gonorrhoeae to extended-spectrum cephalosporins (ESCs) h

275 en mini kit provided the highest ratio of N. gonorrhoeae to human DNA and the most consistent results

276 highlights the role for NspA in enabling N. gonorrhoeae to subvert complement despite LOS phase vari

277 enterica, Haemophilus ducreyi and Neisseria gonorrhoeae, together with BamA's homolog, TamA from E.

278 platform using RNA signatures for Neisseria gonorrhoeae Transcriptome sequencing (RNA-seq) followed

279 genitalium, Chlamydia trachomatis, Neisseria gonorrhoeae, Trichomonas vaginalis, Mycoplasma hominis,

280 f the lipooligosaccharide (LOS) of Neisseria gonorrhoeae undergoes positive selection during human in

281 l markers in the transcriptome profile of N. gonorrhoeae upon minutes of azithromycin exposure.

282 cimens were tested for C. trachomatis and N. gonorrhoeae using a Gen-Probe Aptima Combo 2 assay.

283 odel for the study of the pathogenesis of N. gonorrhoeae using a well-characterized DeltapilT mutant.

284 N. gonorrhoeae was detected from 30 rectal and 40 pharyngea

285 achomatis was detected in 8.7% and Neisseria gonorrhoeae was detected in 6.6%.

286 crobial resistance determinants in Neisseria gonorrhoeae was developed and is publicly accessible.

287 ction of Chlamydia trachomatis and Neisseria gonorrhoeae was established in a multisite, prospective

288 The positivity rate for N. gonorrhoeae was highest for rectal sites (10.4%), follow

289 assay for detection of C. trachomatis or N. gonorrhoeae was observed, although some mailed swabs too

290 imulated infections, if >=10(4) CFU/ml of N. gonorrhoeae was present, sequencing of the large majorit

291 ependent velocity of DNA uptake by Neisseria gonorrhoeae We found that the DNA uptake velocity depend

292 ent risk factors for oropharyngeal Neisseria gonorrhoeae were assessed among MSM routinely universall

293 ndependent risk factors for oropharyngeal N. gonorrhoeae were assessed among MSM routinely universall

294 ctivatable photosensitizing porphyrins in N. gonorrhoeae were identified and quantified using ultrape

295 e transmission clusters (>=10 samples) of N. gonorrhoeae were susceptible to ciprofloxacin, ceftriaxo

296 the cervicovaginal microbiome can modify N. gonorrhoeae, which will enhance successful transmission

297 gnificantly decreased serum resistance of N. gonorrhoeae with either wild-type or truncated LOS.

298 ralia, we show widespread transmission of N. gonorrhoeae within and between population groups.

299 For N. gonorrhoeae, Xpert had higher sensitivity than Aptima, b

300 etion of human DNA with saponin increased N. gonorrhoeae yields in simulated infections but decreased